Abstract
Abstract
Background
To help clinicians provide timely treatment and delay disease progression, it is crucial to identify dementia patients during the mild cognitive impairment (MCI) stage and stratify these MCI patients into early and late MCI stages before they progress to Alzheimer’s disease (AD). In the process of diagnosing MCI and AD in living patients, brain scans are collected using neuroimaging technologies such as computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET). These brain scans measure the volume and molecular activity within the brain resulting in a very promising avenue to diagnose patients early in a minimally invasive manner.
Methods
We have developed an optimal transport based transfer learning model to discriminate between early and late MCI. Combing this transfer learning model with bootstrap aggregation strategy, we overcome the overfitting problem and improve model stability and prediction accuracy.
Results
With the transfer learning methods that we have developed, we outperform the current state of the art MCI stage classification frameworks and show that it is crucial to leverage Alzheimer’s disease and normal control subjects to accurately predict early and late stage cognitive impairment.
Conclusions
Our method is the current state of the art based on benchmark comparisons. This method is a necessary technological stepping stone to widespread clinical usage of MRI-based early detection of AD.
Publisher
Springer Science and Business Media LLC
Subject
Cognitive Neuroscience,Neurology (clinical),Neurology
Reference35 articles.
1. Alzheimer’s Disease Fact Sheet. U.S. Department of Health and Human Services. https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet. Accessed 10 Feb 2021.
2. Niikura T, Tajima H, Kita Y. Neuronal cell death in alzheimer’s disease and a neuroprotective factor, humanin. Curr Neuropharmacol. 2006; 4(2):139–47.
3. Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in alzheimer’s disease. Alzheimers Dement Transl Res Clin Interv. 2018; 4:575–90.
4. Murphy MP, LeVine III H. Alzheimer’s disease and the amyloid- β peptide. J Alzheimers Dis. 2010; 19(1):311–23.
5. Park J-C, Han S-H, Yi D, Byun MS, Lee JH, Jang S, Ko K, Jeon SY, Lee Y-S, Kim YK, et al.Plasma tau/amyloid- β1–42 ratio predicts brain tau deposition and neurodegeneration in alzheimer’s disease. Brain. 2019; 142(3):771–86.
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献